Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Xencor, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
XNCR
Nasdaq
2830
www.xencor.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Xencor, Inc.
[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
- Jan 14th, 2026 1:30 am
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones
- Jan 8th, 2026 6:01 am
Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR)
- Dec 31st, 2025 3:46 am
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
- Dec 9th, 2025 5:00 am
Xencor (XNCR): Assessing Valuation After Net Losses Narrow Sharply in Latest Earnings
- Nov 14th, 2025 4:14 am
Will Sharply Reduced Net Losses Signal a Turning Point for Xencor's (XNCR) Path to Profitability?
- Nov 13th, 2025 2:10 pm
Xencor to Participate at Upcoming Investor Conferences
- Nov 10th, 2025 2:01 pm
Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates
- Nov 5th, 2025 3:35 pm
Xencor: Q3 Earnings Snapshot
- Nov 5th, 2025 2:47 pm
Xencor Reports Third Quarter 2025 Financial Results
- Nov 5th, 2025 2:01 pm
Beaten Down by 35%-Plus: Analysts Say These 2 Oversold Stocks Are Poised to Turn the Corner
- Nov 5th, 2025 4:08 am
Aurinia Pharmaceuticals (AUPH) Surpasses Q3 Earnings and Revenue Estimates
- Nov 4th, 2025 5:10 am
Xencor (XNCR): Evaluating Valuation Following Early XmAb819 Trial Results Announcement
- Oct 28th, 2025 10:53 pm
Could Xencor's (XNCR) Early Cancer Data Reveal a New Edge in Its Innovation Strategy?
- Oct 27th, 2025 8:04 pm
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
- Oct 24th, 2025 10:30 am
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
- Oct 21st, 2025 6:01 am
Xencor Stock Earns Relative Strength Rating Upgrade
- Oct 16th, 2025 11:40 am
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Oct 14th, 2025 10:45 am
Tracking the Evolving Narrative for Xencor After Mixed Analyst Developments
- Oct 8th, 2025 9:08 pm
Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?
- Sep 18th, 2025 8:05 am
Scroll